Drugs / High-Dose trivalent influenza vaccine (Split virion, Inactivated)
High-Dose trivalent influenza vaccine (Split virion, Inactivated)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06641180 | Nov 2024 → Jan 2025 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-Dose trivalent influenza vaccine (Split virion, Inactivated) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641180 ↗ |
| Modality | Vaccine | “High-Dose Inactivated Influenza Vaccine (IIV-HD)” NCT06641180 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT06641180 ↗ |